Most glucagon receptors are found on hepatocytes, but they are also present in the central nervous system, kidney, gastrointestinal tract, and the pancreas [12]
GLP-1 medications such as semaglutide work by influencing appetite regulation, gastric emptying, and metabolic signaling
The most commonly reported side effects of retatrutide in Phase 2 clinical trials are gastrointestinal, including nausea, vomiting, diarrhoea, and constipation
By working with both incretin pathways your body already uses, tirzepatide may support deeper appetite regulation, larger and more sustained weight loss, and better glycemic stability than GLP-1 therapy alone
other GLP-1 RAs
Potential Side Effects, Contraindications, and Safety Questions GLP-1 medications have a well-documented safety profile, and it's worth knowing it before you start - not after your first injection